Literature DB >> 18635422

Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.

J Malyszko1, J S Malyszko, K Pawlak, M Mysliwiec.   

Abstract

PURPOSE: Visfatin and apelin are novel adipocytokines that have recently generated much interest. The aim of the study was to assess visfatin and apelin in correlation with markers of endothelial cell injury and inflammation in 22 patients with chronic kidney disease-CKD and 22 age- and sex-matched healthy volunteers.
METHODS: We assessed visfatin, apelin, markers of coagulation: TAT (thrombin-antithrombin complexes), prothrombin fragments 1+2; fibrinolysis: tPA (tissue plasminogen activator), PAI-1 (plasminogen activator inhibitor), PAP (plasmin-antiplasmin complexes); endothelial function/injury: vWF (von Willebrand factor), thrombomodulin, ICAM (intracellular adhesion molecule), VCAM (vascular cell adhesion molecule), CD146, CD40L, CD44, E-selectin, inflammation: hsCRP.
RESULTS: Triglycerides, hsCRP, creatinine, vWF, prothrombin fragments 1+2, TAT, thrombomodulin, ICAM, VCAM, CD146, CD44, CD40L, PAI-1, PAP, visfatin and E-selectin were elevated in chronic kidney disease patients when compared with the control group. Visfatin correlated significantly in patients with chronic kidney disease, in univariate analysis, with CD40L (r=-0.27, p<0.05), apelin (r=0.27, p<0.05), ICAM (r=0.26, p<0.05), VCAM (r=0.31, p<0.05) and tended to correlate with CD146 (r=0.21, p=0.10). Apelin correlated significantly with E-selectin (r=0.31, p<0.05) and VCAM (r=0.31, p<0.05). In the healthy volunteers visfatin correlated significantly with ICAM (r=-0.37, p<0.05) and serum creatinine (0.38, p<0.05).
CONCLUSIONS: Elevated visfatin in CKD patients may be due to renal failure and/or inflammation. Adipocytokines related to adhesion molecules might support the importance of inflammation/endothelial cell injury in the pathogenesis of atherosclerosis and its consequences in CKD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635422     DOI: 10.2478/v10039-008-0024-x

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  13 in total

1.  Arsenic and Chronic Kidney Disease: A Systematic Review.

Authors:  Laura Zheng; Chin-Chi Kuo; Jeffrey Fadrowski; Jackie Agnew; Virginia M Weaver; Ana Navas-Acien
Journal:  Curr Environ Health Rep       Date:  2014-09-01

2.  Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.

Authors:  Fernanda Genre; Raquel López-Mejías; José A Miranda-Filloy; Begoña Ubilla; Verónica Mijares; Beatriz Carnero-López; Inés Gómez-Acebo; Trinidad Dierssen-Sotos; Sara Remuzgo-Martínez; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Rheumatol Int       Date:  2015-07-05       Impact factor: 2.631

3.  The association of urine arsenic with prevalent and incident chronic kidney disease: evidence from the Strong Heart Study.

Authors:  Laura Y Zheng; Jason G Umans; Fawn Yeh; Kevin A Francesconi; Walter Goessler; Ellen K Silbergeld; Karen Bandeen-Roche; Eliseo Guallar; Barbara V Howard; Virginia M Weaver; Ana Navas-Acien
Journal:  Epidemiology       Date:  2015-07       Impact factor: 4.822

4.  Urine arsenic and prevalent albuminuria: evidence from a population-based study.

Authors:  Laura Y Zheng; Jason G Umans; Maria Tellez-Plaza; Fawn Yeh; Kevin A Francesconi; Walter Goessler; Ellen K Silbergeld; Eliseo Guallar; Barbara V Howard; Virginia M Weaver; Ana Navas-Acien
Journal:  Am J Kidney Dis       Date:  2012-11-09       Impact factor: 8.860

5.  Effects of apelin and leptin on renal functions following renal ischemia/reperfusion: An experimental study.

Authors:  Tamer Sagiroglu; Nese Torun; Mehmet Yagci; Tülin Yalta; Gönül Sagiroglu; Serhat Oguz
Journal:  Exp Ther Med       Date:  2012-02-29       Impact factor: 2.447

Review 6.  Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.

Authors:  Fernanda Genre; Raquel López-Mejías; José A Miranda-Filloy; Begoña Ubilla; Beatriz Carnero-López; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Biomed Res Int       Date:  2014-03-18       Impact factor: 3.411

7.  Increased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients.

Authors:  Chien-Yi Hsu; Po-Hsun Huang; Tz-Heng Chen; Chia-Hung Chiang; Hsin-Bang Leu; Chin-Chou Huang; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Am J Hypertens       Date:  2015-08-22       Impact factor: 2.689

Review 8.  Visfatin/Nampt: an adipokine with cardiovascular impact.

Authors:  Tania Romacho; Carlos F Sánchez-Ferrer; Concepción Peiró
Journal:  Mediators Inflamm       Date:  2013-06-16       Impact factor: 4.711

9.  Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis.

Authors:  Manuela Di Franco; Francesca Romana Spinelli; Alessio Metere; Maria Chiara Gerardi; Virginia Conti; Francesca Boccalini; Cristina Iannuccelli; Francesco Ciciarello; Luciano Agati; Guido Valesini
Journal:  Mediators Inflamm       Date:  2012-08-07       Impact factor: 4.711

10.  What is the role of apelin regarding cardiovascular risk and progression of renal disease in type 2 diabetic patients with diabetic nephropathy?

Authors:  Ana Paula Silva; André Fragoso; Claudia Silva; Carla Viegas; Nelson Tavares; Patrícia Guilherme; Nélio Santos; Fátima Rato; Ana Camacho; Cidália Cavaco; Victor Pereira; Marilia Faísca; João Ataíde; Ilídio Jesus; Pedro Neves
Journal:  Biomed Res Int       Date:  2013-09-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.